CAJ | 학술논문

肺癌是最常见的恶性肿瘤之一，也是目前癌症死亡的首要原因，其中约80％为非小细胞肺癌（Non-small Cell Lung Cancers，NSCLC）。表皮生长因子受体（Epidermal Growth Factor Receptor，EGFR）驱动基因在肺癌的发生发展过程中起重要作用，近年来，以吉非替尼和厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂（Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors，EGFR-TKI）在 NSCLC 的分子靶向治疗中发挥了巨大的作用，给NSCLC 患者带来了福音。然而，无论近期效果如何，最终患者都不可避免地产生耐药及病情进展。本文主要对近年来EGFR-TKI 继发性耐药的发生机制及耐药后的对策作一综述，以期更好地指导 NSCLC 的治疗。
폐암시최상견적악성종류지일，야시목전암증사망적수요원인，기중약80％위비소세포폐암（Non-small Cell Lung Cancers，NSCLC）。표피생장인자수체（Epidermal Growth Factor Receptor，EGFR）구동기인재폐암적발생발전과정중기중요작용，근년래，이길비체니화액락체니위대표적표피생장인자수체락안산격매억제제（Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors，EGFR-TKI）재 NSCLC 적분자파향치료중발휘료거대적작용，급NSCLC 환자대래료복음。연이，무론근기효과여하，최종환자도불가피면지산생내약급병정진전。본문주요대근년래EGFR-TKI 계발성내약적발생궤제급내약후적대책작일종술，이기경호지지도 NSCLC 적치료。
Lung cancer, in which about 80% are non-small cell lung cancers (NSCLC), is one of the most common malignant tumors, and also the leading cause of cancer death currently. The epidermal growth factor receptor (EGFR) driver gene plays an important role in the occurrence and development of lung cancer. In recent years, the epidermal growth factor receptor tyrosine ki-nase inhibitors (EGFR-TKI), especially gefitinib and erlotinib, have played a significant role in the molecular and targeted therapy of NSCLC, and brought in good news for NSCLC patients. However, no matter how effective it is in the short term, the patients will inevitably develop into drug resistance and progressive disease in the long run. In this paper, we made a review on the mechanism of EGFR-TKI secondary drug resistance and the countermeasures on drug resistance after treatment, so as to guide the treatment of NSCLC better.